222. Primary nephrotic syndrome Clinical trials / Disease details
Clinical trials : 285 / Drugs : 285 - (DrugBank : 108) / Drug target genes : 62 - Drug target pathways : 191
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02399462 (ClinicalTrials.gov) | March 2021 | 8/1/2015 | Acthar for Treatment of Post-transplant FSGS | Acthar for Treatment of Post-transplant FSGS | FSGS;Renal Transplantation;Kidney Transplantation | Drug: Acthar | University of North Carolina, Chapel Hill | Mallinckrodt | Withdrawn | 18 Years | N/A | All | 0 | Phase 4 | United States |
| 2 | NCT02683889 (ClinicalTrials.gov) | February 1, 2019 | 5/2/2016 | Use of Acthar in Patients With FSGS That Will be Undergoing Renal Transplantation | The Use of Acthar (ACTH) in Patients With Focal Segmental Glomerulosclerosis (FSGS) Who Have Developed Chronic Kidney Disease Stage V (CKD) or End Stage Renal Disease (ESRD) and Are Undergoing a Renal Transplant | FSGS | Drug: Acthar | University of Colorado, Denver | NULL | Recruiting | 18 Years | 80 Years | All | 20 | Phase 3 | United States |
| 3 | NCT03025828 (ClinicalTrials.gov) | March 19, 2018 | 17/1/2017 | Adrenocorticotropic Hormone in Membranous Nephropathy | Changes in Autoreactive Memory B Cells as Biomarker of Response to Adrenocorticotropic Hormone in Patients With Membranous Nephropathy | Membranous Nephropathy | Drug: ACTHar | Icahn School of Medicine at Mount Sinai | NULL | Completed | 18 Years | 70 Years | All | 5 | Phase 4 | United States |
| 4 | NCT02633046 (ClinicalTrials.gov) | October 10, 2016 | 15/12/2015 | Acthar for Treatment-Resistant or Treatment-Intolerant Proteinuria | Treatment of Proteinuria Due to Treatment Resistant or Treatment Intolerant Idiopathic Focal Segmental Glomerulosclerosis: A Prospective Study of Acthar (PODOCYTE) | Idiopathic Focal Segmental Glomerulosclerosis | Drug: Acthar Gel | Mallinckrodt ARD LLC | NULL | Completed | 18 Years | N/A | All | 63 | Phase 4 | United States;Argentina;Australia;Chile;Mexico;Peru;Turkey;Canada;Hong Kong;New Zealand;Puerto Rico |
| 5 | NCT01386554 (ClinicalTrials.gov) | August 2011 | 29/6/2011 | Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients | A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN) | Proteinuria;Idiopathic Membranous Nephropathy | Drug: Repository Corticotropin Injection;Drug: Placebo | Mallinckrodt | NULL | Completed | 18 Years | N/A | All | 60 | Phase 4 | United States;Canada;Chile;Mexico;Turkey |
| 6 | NCT01155141 (ClinicalTrials.gov) | September 2009 | 29/6/2010 | Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTH | Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTH | Kidney Diseases | Drug: H.P. Acthar Gel | Stanford University | Mallinckrodt | Completed | 16 Years | 65 Years | All | 15 | Phase 4 | United States |